Partners
Collaboration accelerates discovery
AVIPERO Bio works with leading academic institutions, clinical research organisations, and industry partners to advance our allosteric integrin modulator platform.
Partnering
Built to be partnered, region by region.
Avipero is a focused company holding a single mechanism with breadth across oncology, neurology and inflammation. That combination suits regional development partnerships rather than a single global licence: a partner with depth in one territory and one indication can move faster than we can alone, without foreclosing the rest of the platform.
We are open to discussions on territory-specific development and commercialisation rights, co-development structures, and antibody-engineering collaborations including ADC formats.
Business development
[email protected]Academic institutions
We collaborate with university research groups and institutes to deepen our mechanistic understanding of integrin allostery and identify new therapeutic opportunities.
Clinical research organisations
We partner with CROs and clinical networks to design and execute rigorous early-phase clinical studies with robust translational endpoints.
Pharmaceutical companies
We are open to co-development, licensing, and strategic alliance discussions with pharmaceutical and biotechnology companies seeking differentiated pipeline assets.
Patient organisations
We engage with patient advocacy groups and disease foundations to ensure our development programs remain grounded in unmet clinical need.
Questions
What investors and analysts ask first.
Is Avipero still operating?
Yes. AVIPERO Bio is an active international pharmaceutical company incorporated in both the United Kingdom (Avipero Ltd, SC353945) and the United States (Avipero Bio, Delaware). The company is preclinical stage and is preparing an FDA INTERACT meeting request for its lead oncology programme. Third-party directories carrying a "defunct" or "under construction" status are out of date.
What is AVI001?
AVI001 is the development designation for JB1a, a humanised monoclonal antibody that binds the hybrid domain of β1 integrin and holds the receptor in its low-affinity resting conformation. There is no separate small-molecule programme.
How does allosteric β1 modulation differ from earlier integrin drugs?
Cilengitide and volociximab were ligand-competitive: they occupied the binding pocket to block adhesion outright, and both failed in clinical development. AVI001 does not compete for the ligand site. It binds a regulatory interface remote from that pocket and prevents the receptor from switching into its high-affinity state.
Is Avipero open to regional licensing partnerships?
Yes. Avipero is open to discussions on territory-specific development and commercialisation rights, co-development structures, and antibody-engineering collaborations including ADC formats. Enquiries go to [email protected].
Interested in partnering with AVIPERO Bio?
We welcome enquiries from potential partners across academia, clinical research, and industry. Get in touch to start a conversation.
Contact us